- Report
- September 2022
- 140 Pages
Global
From €3819EUR$3,950USD£3,282GBP
- Report
- January 2022
- 200 Pages
Global
From €7250EUR$7,500USD£6,232GBP
- Report
- September 2023
- 90 Pages
Egypt
From €3384EUR$3,500USD£2,908GBP
- Report
- August 2023
- 74 Pages
Canada
From €3384EUR$3,500USD£2,908GBP
- Report
- August 2023
- 73 Pages
Israel
From €3384EUR$3,500USD£2,908GBP
- Report
- November 2020
- 101 Pages
Global
€21268EUR$22,000USD£18,280GBP
- Report
- June 2018
- 21 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Report
- June 2018
- 15 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Report
- June 2018
- 17 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Report
- June 2018
- 15 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Report
- June 2018
- 546 Pages
Global
From €21268EUR$22,000USD£18,280GBP
- Report
- July 2023
- 108 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- July 2022
- 93 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- October 2022
- 63 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- December 2019
- 184 Pages
Global
From €5191EUR$5,370USD£4,462GBP
- Report
- September 2023
- 160 Pages
Global
From €2899EUR$2,999USD£2,492GBP
- Report
- February 2024
- 180 Pages
Global
From €5316EUR$5,499USD£4,569GBP
The PCSK9 Inhibitor market is a subset of the Cardiovascular Drugs market. PCSK9 Inhibitors are a class of drugs used to lower cholesterol levels in patients with cardiovascular disease. These drugs work by blocking the action of the PCSK9 enzyme, which is responsible for breaking down LDL cholesterol in the body. PCSK9 Inhibitors are typically prescribed in combination with other cholesterol-lowering medications, such as statins.
PCSK9 Inhibitors have been shown to be effective in reducing LDL cholesterol levels, and have been approved for use in the United States and Europe. However, due to their high cost, they are not widely used.
Companies in the PCSK9 Inhibitor market include Amgen, Sanofi, Regeneron, and Pfizer. Show Less Read more
